Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Long-Term Deferred Tax (2020 - 2024)

Inmune Bio (INMB) has disclosed Long-Term Deferred Tax for 5 consecutive years, with $25.7 million as the latest value for Q4 2024.

  • Quarterly Long-Term Deferred Tax rose 31.12% to $25.7 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $25.7 million through Dec 2024, up 31.12% year-over-year, with the annual reading at $25.7 million for FY2024, 31.12% up from the prior year.
  • Long-Term Deferred Tax hit $25.7 million in Q4 2024 for Inmune Bio, up from $545000.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $25.7 million in Q4 2024 to a low of $545000.0 in Q3 2024.
  • Historically, Long-Term Deferred Tax has averaged $10.1 million across 5 years, with a median of $6.8 million in 2021.
  • Biggest five-year swings in Long-Term Deferred Tax: surged 101.71% in 2022 and later soared 31.12% in 2024.
  • Year by year, Long-Term Deferred Tax stood at $3.5 million in 2020, then soared by 91.49% to $6.8 million in 2021, then surged by 101.71% to $13.7 million in 2022, then surged by 43.07% to $19.6 million in 2023, then soared by 31.12% to $25.7 million in 2024.
  • Business Quant data shows Long-Term Deferred Tax for INMB at $25.7 million in Q4 2024, $545000.0 in Q3 2024, and $590000.0 in Q2 2024.